Efficacy and tolerability of the novel triple reuptake inhibitor amitifadine in the treatment of patients with major depressive disorder: a randomized, double-blind, placebo-controlled trial. [electronic resource]
Producer: 20120326Description: 64-71 p. digitalISSN:- 1879-1379
- Adolescent
- Adult
- Aged
- Antidepressive Agents -- therapeutic use
- Aza Compounds -- therapeutic use
- Bridged Bicyclo Compounds, Heterocyclic -- therapeutic use
- Depressive Disorder, Major -- drug therapy
- Double-Blind Method
- Female
- Follow-Up Studies
- Humans
- International Cooperation
- Male
- Middle Aged
- Psychiatric Status Rating Scales
- Treatment Outcome
- Young Adult
No physical items for this record
Publication Type: Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.